Selegiline have poor brain uptake due to its poor aqueous solubility, so the study aimed to develop its microemulsion formulation to enhance the solubility and to accomplish the intranasal delivery of the drug to brain. Selegiline microemulsion (SME) was prepared using 1% labrafil M 1944 CS as oil, 25% tween 80 as surfactant and 25% transcutol P as co-surfactant by titration method. Pseudo ternary phase diagram was constructed to determine the microemulsion existing zone. Optimized microemulsion was characterized for their % transmittance, globule size, zeta potential and viscocity. Mucoadhesive microemulsion containing Selegiline (SMME) was prepared using chitosan in different concentrations. Nasal ciliotoxicity studies were carried out for SME and ME 3 using sheep nasal mucosa. Developed formulations were subjected for stability study as per the ICH guidelines for one month. Drug release from the formulations was carried out through excised sheep nasal mucosa using modified franz diffusion cell. The optimized SME was transparent with mean globule size 54.57 nm and zeta potential +21mV and PDI of 0.180. Stability study revealed that SME and ME3 were stable for 1 months. Microscope investigation revealed no marked damage on the sheep nasal mucosa after nasal application of SME and ME 3 for 1hr. Ex-vivo release study was performed of the optimized batch for 8 hrs. Transmission electron microscopy was performed and the image showed spherical globule with size of 72.85 nm. Based on the results, ME3 and SME were stable and can target the drug to brain through intranasal route and thus can play as an alternative for conventional dosage form.
Loading....